BR112015014842A2 - apoptosis inducing agent - Google Patents

apoptosis inducing agent

Info

Publication number
BR112015014842A2
BR112015014842A2 BR112015014842A BR112015014842A BR112015014842A2 BR 112015014842 A2 BR112015014842 A2 BR 112015014842A2 BR 112015014842 A BR112015014842 A BR 112015014842A BR 112015014842 A BR112015014842 A BR 112015014842A BR 112015014842 A2 BR112015014842 A2 BR 112015014842A2
Authority
BR
Brazil
Prior art keywords
inducing agent
apoptosis inducing
apoptosis
agent
inducing
Prior art date
Application number
BR112015014842A
Other languages
Portuguese (pt)
Inventor
Nishita Hiroki
Tanaka Hiroyuki
Niitsu Yoshiro
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of BR112015014842A2 publication Critical patent/BR112015014842A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01018—Glutathione transferase (2.5.1.18)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112015014842A 2012-12-20 2013-12-20 apoptosis inducing agent BR112015014842A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012278706A JP6340162B2 (en) 2012-12-20 2012-12-20 Apoptosis inducer
PCT/JP2013/084225 WO2014098210A1 (en) 2012-12-20 2013-12-20 Apoptosis-inducing agent

Publications (1)

Publication Number Publication Date
BR112015014842A2 true BR112015014842A2 (en) 2017-07-11

Family

ID=50978526

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015014842A BR112015014842A2 (en) 2012-12-20 2013-12-20 apoptosis inducing agent

Country Status (11)

Country Link
US (1) US9914983B2 (en)
EP (1) EP2937099A4 (en)
JP (1) JP6340162B2 (en)
KR (1) KR20150095780A (en)
CN (1) CN104884090A (en)
AU (1) AU2013364893A1 (en)
BR (1) BR112015014842A2 (en)
CA (1) CA2895690C (en)
RU (1) RU2015129287A (en)
TW (1) TW201440788A (en)
WO (1) WO2014098210A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10264976B2 (en) 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
US11045488B2 (en) 2014-12-26 2021-06-29 Nitto Denko Corporation RNA interference agents for GST-π gene modulation
US10792299B2 (en) 2014-12-26 2020-10-06 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
US20180002702A1 (en) 2014-12-26 2018-01-04 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation
ES2789049T3 (en) * 2014-12-26 2020-10-23 Nitto Denko Corp RNA Interference Agents for GST-pi Gene Modulation
CN113577290B (en) * 2014-12-26 2023-10-24 日东电工株式会社 Cell death inducing agent, cell proliferation inhibiting agent, and pharmaceutical composition for treating diseases caused by abnormal cell proliferation
US20160187319A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth
JP6864990B2 (en) * 2015-04-16 2021-04-28 日東電工株式会社 A cell death inducer for cells having a BRAF gene mutation, a growth inhibitor of the cells, and a pharmaceutical composition for treating a disease caused by abnormal growth of the cells.
RU2760835C2 (en) * 2015-04-16 2021-11-30 Нитто Денко Корпорейшн Agent inducing cell death for cells having braf gene mutations, agent suppressing growth of such cells, and pharmaceutical composition for the therapy of diseases caused by growth defect of such cells
CN106265660B (en) * 2015-05-21 2019-08-02 中国科学院合肥物质科学研究院 Purposes of the A674563 in the acute leukemia for carrying FLT3 mutated genes
JP6899201B2 (en) 2016-06-23 2021-07-07 日東電工株式会社 Cell death inducer, cell proliferation inhibitor and therapeutic pharmaceutical composition for diseases caused by abnormal cell proliferation

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US5811119A (en) 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
ATE154514T1 (en) 1989-09-29 1997-07-15 Jolla Cancer Res Found INHIBITION OF TRANSFORMING GROWTH FACTOR TO PREVENT EXTRACELLULAR MATRIX ACCUMULATION
US20040028682A1 (en) 1989-09-29 2004-02-12 Border Wayne A. Inhibiting transforming growth factor beta to prevent accumulation of extracellular matrix
US5786336A (en) 1991-04-29 1998-07-28 Terrapin Technologies, Inc. Target-selective protocols based on mimics
AU670777B2 (en) 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
JPH08268906A (en) 1995-03-31 1996-10-15 Sumitomo Pharmaceut Co Ltd Pulmonary fibrosis-preventing agent
JPH11507056A (en) 1995-06-07 1999-06-22 テラピン テクノロジーズ、インク． Metabolic effects of glutathione analogs
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
US5851538A (en) 1995-12-29 1998-12-22 Advanced Polymer Systems, Inc. Retinoid formulations in porous microspheres for reduced irritation and enhanced stability
US6183774B1 (en) 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
JP2001514873A (en) 1997-08-20 2001-09-18 ソーマジェニックス インコーポレイテッド Antisense and antigene therapeutics with improved binding properties and methods of using them
JPH11269076A (en) 1998-01-22 1999-10-05 Seikagaku Kogyo Co Ltd Anti-fibrillating agent
CA2328731A1 (en) 1998-04-16 1999-10-28 Atsushi Imaizumi Glutathione derivatives and dosage forms thereof
JP4509395B2 (en) 1999-04-27 2010-07-21 田辺三菱製薬株式会社 Preventive and therapeutic drug for liver disease
US20020041898A1 (en) 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
WO2001072283A1 (en) 2000-03-29 2001-10-04 Aradigm Corporation Cationic liposomes
JP2002047211A (en) 2000-08-04 2002-02-12 Japan Science & Technology Corp Combination of fat-soluble substance with physiologically active high polymer and method for introduction into cell nulceus
EP1392366A4 (en) 2001-04-13 2005-01-19 Population Council Inc Nuclear receptor-mediated introduction of a pna into cell nuclei
JP4547696B2 (en) 2001-06-07 2010-09-22 第一三共株式会社 Cirrhosis prevention / treatment agent
JP2002371006A (en) 2001-06-11 2002-12-26 Mochida Pharmaceut Co Ltd Prophylactic and/or progress inhibitor against pulmonary fibrosis
JP2003119138A (en) 2001-10-09 2003-04-23 Tohoku Techno Arch Co Ltd Agent for prevention and treatment of interstitial pneumonia and/or pulmonary fibrosis
EP1453545B1 (en) 2001-10-30 2007-04-18 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of retinoic acid
CN1612930A (en) 2001-11-21 2005-05-04 三菱化学株式会社 Method of inhibiting gene expression
JP3803318B2 (en) 2001-11-21 2006-08-02 株式会社ＲＮＡｉ Gene expression inhibition method
EP1465622A1 (en) 2001-11-26 2004-10-13 Arachnova Therapeutics Ltd. Use of ppar activators for the treatment of pulmonary fibrosis
DE60326833D1 (en) 2002-05-15 2009-05-07 Endocyte Inc VITAMIN MITOMYCIN CONJUGATES
JP4488512B2 (en) 2002-06-19 2010-06-23 レイベン バイオテクノロジーズ，インコーポレイティド Novel RAAG10 cell surface target and antibody family that recognizes the target
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
JP2006502153A (en) 2002-08-27 2006-01-19 インターミューン インコーポレイティッド Treatment of idiopathic pulmonary fibrosis
US20050191302A1 (en) 2002-08-29 2005-09-01 University Of Southampton Treatment for liver disease
CA2505633A1 (en) 2002-11-13 2004-05-27 Raven Biotechnologies, Inc. Antigen pipa and antibodies that bind thereto
EP2529758A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
JP2006522158A (en) 2003-04-03 2006-09-28 アルナイラム ファーマシューティカルズ インコーポレイテッド iRNA complex
CN101048425B (en) 2003-09-18 2012-12-26 雷文生物技术公司 KID3 and KID3 antibodies that bind thereto
WO2005084702A1 (en) 2004-03-02 2005-09-15 Hokkaido Technology Licensing Office Co., Ltd. Agent for preventing and treating organ fibrosis
TW200538149A (en) 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
US7358223B2 (en) 2004-10-04 2008-04-15 Nitto Denko Corporation Biodegradable cationic polymers
US20130171240A1 (en) 2004-12-22 2013-07-04 Nitto Denko Corporation Drug carrier and drug carrier kit for inhibiting fibrosis
ES2900801T3 (en) 2004-12-22 2022-03-18 Nitto Denko Corp Drug carrier and drug carrier kit to inhibit fibrosis
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
JP2009221164A (en) 2008-03-17 2009-10-01 Nitto Denko Corp Drug for treating pulmonary fibrosis
AU2006206478B2 (en) 2005-01-19 2012-04-12 The Trustees Of The University Of Pennsylvania Regulation of autophagy and cell survival
GB0524987D0 (en) 2005-12-08 2006-01-18 Ge Healthcare Ltd Novel imaging agents for fibrosis
JP5342834B2 (en) 2008-09-05 2013-11-13 日東電工株式会社 Treatment agent for myelofibrosis
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
UA95641C2 (en) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
TWI407971B (en) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
US20130210744A1 (en) 2007-03-30 2013-08-15 Nitto Denko Corporation Targeting agent for cancer cell or cancer-associated fibroblast
US20080312174A1 (en) 2007-06-05 2008-12-18 Nitto Denko Corporation Water soluble crosslinked polymers
CA2698812A1 (en) 2007-09-14 2009-03-19 Nitto Denko Corporation Drug carriers
KR20110051214A (en) 2008-07-30 2011-05-17 닛토덴코 가부시키가이샤 Drug carriers
TWI556831B (en) 2008-09-12 2016-11-11 日東電工股份有限公司 Imaging agents of fibrotic diseases
EP3012324A3 (en) 2009-12-09 2016-07-06 Nitto Denko Corporation Modulation of hsp47 expression
CA2802414C (en) 2010-06-17 2018-01-09 Nitto Denko Corporation Agent for treating renal fibrosis
JP5950428B2 (en) 2010-08-05 2016-07-13 日東電工株式会社 Composition for regenerating normal tissue from fibrotic tissue
US20160015656A2 (en) 2010-08-05 2016-01-21 Nitto Denko Corporation Composition for regenerating normal tissue from fibrotic tissue
RU2632888C2 (en) 2011-06-08 2017-10-11 Нитто Денко Корпорейшн Compounds for targeted delivery of medicine and enhanced siphk activity
US20140315975A1 (en) 2011-06-21 2014-10-23 Nitto Denko Corporation Apoptosis-inducing agent
US20130064815A1 (en) 2011-09-12 2013-03-14 The Trustees Of Princeton University Inducing apoptosis in quiescent cells
EP2781225B1 (en) 2011-11-18 2019-10-09 Nitto Denko Corporation Intestinal fibrosis treatment agent

Also Published As

Publication number Publication date
KR20150095780A (en) 2015-08-21
JP6340162B2 (en) 2018-06-06
RU2015129287A (en) 2017-01-25
AU2013364893A1 (en) 2015-07-09
EP2937099A4 (en) 2016-07-27
US20150328248A1 (en) 2015-11-19
US9914983B2 (en) 2018-03-13
CN104884090A (en) 2015-09-02
JP2014122175A (en) 2014-07-03
WO2014098210A1 (en) 2014-06-26
CA2895690A1 (en) 2014-06-26
EP2937099A1 (en) 2015-10-28
CA2895690C (en) 2021-08-10
TW201440788A (en) 2014-11-01

Similar Documents

Publication Publication Date Title
GB201321746D0 (en) Therapeutic agents
GB201321743D0 (en) Therapeutic agents
GB2529950B (en) Patient support
GB2532671B (en) Patient support
GB201321738D0 (en) Therapeutic Agents
GB201321736D0 (en) Therapeutic agents
GB201321729D0 (en) Therapeutic agents
GB201321733D0 (en) Therapeutic agents
GB201321728D0 (en) Therapeutic agents
DK2891492T3 (en) ENDOPARASITE CONTROL AGENT
GB201321730D0 (en) Therapeutic agents
GB201321739D0 (en) Therapeutic agents
BR112015014842A2 (en) apoptosis inducing agent
GB201321741D0 (en) Therapeutic agents
GB201321740D0 (en) Therapeutic agents
GB201321732D0 (en) Therapeutic agents
GB201321734D0 (en) Therapeutic Agents
GB201321737D0 (en) Therapeutic Agents
GB201321744D0 (en) Therapeutic agents
GB201321742D0 (en) Therapeutic agents
GB201321735D0 (en) Therapeutic Agents
GB201321745D0 (en) Therapeutic agents
GB201321731D0 (en) Therapeutic agents
GB201321748D0 (en) Therapeutic agents
GB201308440D0 (en) Therapeutic

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]